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Bradyarrhythmias are an important cause of mortality in heart failure and previous studies indicate 
a mechanistic role for electrical remodelling of the key pacemaking ion channel HCN4 in this process. 
Here we show that, in a mouse model of heart failure in which there is sinus bradycardia, there is 
upregulation of a microRNA (miR‑370‑3p), downregulation of the pacemaker ion channel, HCN4, 
and downregulation of the corresponding ionic current, If, in the sinus node. In vitro, exogenous 
miR‑370‑3p inhibits HCN4 mRNA and causes downregulation of HCN4 protein, downregulation of If, 
and bradycardia in the isolated sinus node. In vivo, intraperitoneal injection of an antimiR to miR‑
370‑3p into heart failure mice silences miR‑370‑3p and restores HCN4 mRNA and protein and If in the 
sinus node and blunts the sinus bradycardia. In addition, it partially restores ventricular function and 
reduces mortality. This represents a novel approach to heart failure treatment.
Heart failure is a major health problem affecting ~ 26 million people worldwide and is one of the leading causes 
of hospitalisation in USA and Europe, resulting in over 1 million admissions/year as a primary  diagnosis1. Heart 
failure patients often have a relatively fast heart rate (> 70 beats/min)2,3. β-blocker and ivabradine treatment 
received by heart failure patients lowers the heart  rate4,5, which may or may not be the mechanism underlying 
the protective effects of these  medications4. Nevertheless, and paradoxically, bradyarrhythmias (excessively slow 
heart rates and rhythms) account for up to half of the deaths of end-stage heart failure  patients6–8. In the human 
and animal models, there is dysfunction of the pacemaker of the heart, the sinus node, in heart failure: there 
is a decrease in the intrinsic heart rate (the heart rate set by the sinus node in the absence of autonomic nerve 
activity) and an increase in the corrected sinus node recovery time (a frequently used measure of the function-
ing of the sinus node)9–13. The dysfunction of the sinus node in heart failure has been attributed to  fibrosis14 
and also remodelling of ion channels and corresponding ionic currents underlying the functioning of the sinus 
 node10,11,15,16. In particular, it has been attributed to a downregulation of the important pacemaker ion channel, 
HCN4, and the corresponding funny current, If11,15; however, the cause of the remodelling is not known.
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MicroRNAs (or miRs) are a class of abundant, non-coding RNA of 19–25 nucleotides length and are evolu-
tionarily conserved regulatory  molecules17. MicroRNAs negatively regulate gene expression at the post-transcrip-
tional level by translational repression or degradation of  mRNA18. 2,588 mature microRNAs are listed in ‘miR-
Base’ for Homo sapiens19. MicroRNAs are central players in gene regulation: computational prediction suggests 
that > 60% of all mammalian protein-coding genes are conserved targets of microRNAs, while every microRNA 
can potentially target hundreds of different  genes20. MicroRNAs have been implicated in cardiac development, 
cardiac arrhythmias, myocardial infarction and pressure overload-induced cardiac  hypertrophy21–23. For example, 
patients with unstable angina pectoris show a highly significant upregulation of various microRNAs including 
miR-370 in the blood compared to those with stable angina  pectoris24. Elevated expression of miR-370 can pos-
sibly be used to stratify coronary artery disease patients that are at risk of acute coronary  events25. In another 
study, miR-370 levels in the blood were found to be significantly higher in patients with type 2 diabetes and 
coronary artery  disease26.
Here we show a new role for miR-370-3p. We show that in a mouse model of heart failure there is an 
upregulation of miR-370-3p in the sinus node (but not in ventricular muscle) and this results in a downregula-
tion of HCN4 and If and consequently sinus bradycardia. In vivo an antimiR (a small molecule that silences a 
particular microRNA) to miR-370-3p blunts the heart failure-induced sinus bradycardia. In addition, it also 
partially restores whole heart function (e.g. left ventricle fractional shortening), restores body weight and reduces 
mortality.
Results
Heart failure produces sinus bradycardia and first‑degree heart block. In mice, transverse aortic 
constriction (TAC) was used to produce pressure overload-induced heart failure (a commonly used experimen-
tal  model27). From 20 days following TAC surgery, mice began showing characteristic signs of heart failure and 
on reaching pre-defined end-points (e.g. loss of more than 20% of body weight) had to be sacrificed (Fig. 1a). 
60 days after surgery, 65% of the heart failure mice had reached the end points, whereas none of the control 
(sham-operated) mice had (Fig. 1a). Compared with the control mice, heart failure mice had a reduced body 
weight (Fig. 1b, c), larger, heavier hearts (hypertrophied; Fig. 1d, e) and a greater heart weight to tibia length 
ratio as well as heart weight to body weight ratio (Fig. 1f; Supplementary Fig. 1a). Echocardiography showed 
an enlargement of the left ventricle in the heart failure mice as compared with the control mice (Fig. 2a); this 
was confirmed by significant increases in left ventricle mass and internal dimension during diastole (LVIDd) 
and systole (LVIDs) in the heart failure mice (Fig. 2b–d; Supplementary Table 1). In the heart failure mice, left 
ventricular contractile dysfunction was prominent—there was reduced left ventricle fractional shortening and 
ejection fraction (Fig. 2a, e; Supplementary Fig. 1b, c; Supplementary Table 1). The left ventricle fractional short-
ening was low in this study (Fig. 2e; in the conscious mouse it is ~ 60%), but consistent with that in other studies 
on the anaesthetised  mouse28.
The heart rate was recorded in vivo non-invasively from unrestrained and conscious mice using an ECGenie; 
there was a sinus bradycardia in the heart failure mice (the heart rate was significantly slower than that of the 
control mice) and the bradycardia worsened with time (Fig. 3a, b). The ECG was recorded in vivo in the anaes-
thetised mouse. In the heart failure mice, there was a significant increase of the PR interval (first-degree heart 
block) and QRS duration, indicating slowing of conduction through the atrioventricular node and His-Purkinje 
system (Fig. 3c, d), two other characteristics of heart  failure29. There was also an increase in the QT and cor-
rected QT intervals (Fig. 3e, f), again characteristic of heart  failure30. In vivo, the heart rate is influenced by the 
autonomic nervous system and it is also important to measure the intrinsic heart rate (in the absence of any such 
influence). This was measured in isolated sinus node preparations and the intrinsic heart rate was significantly 
slower in the heart failure mice (Fig. 3g). Together, these data demonstrate that in the mouse TAC model of 
heart failure there is dysfunction of all three parts of the cardiac conduction system (sinus node, atrioventricular 
node and His-Purkinje system) as there is in heart failure  patients29. In heart failure, contrary to the bradycardia 
observed in the conscious mouse and in the isolated sinus node preparation (Fig. 3a, g), a relative tachycardia 
was observed in vivo in the anaesthetised mouse (Supplementary Fig. 2). The apparent tachycardia is consistent 
with previous studies using the TAC model and may be the result of the well-known effect of anaesthetic on the 
autonomic nervous system and cardiac ion  channels31,32.
Fig.1.  Silencing miR-370-3p improves mortality and heart weight in heart failure. (a) Percentage survival of 
control mice given PBS (black trace; subject to sham operation; n = 14), heart failure mice given PBS (red trace, 
subject to TAC surgery; n = 17), control mice given antimiR-370-3p (grey trace; subject to sham operation; n = 5) 
and heart failure mice given antimiR-370-3p (blue trace, subject to TAC surgery; n = 20) following TAC surgery. 
P < 0.05; log-rank (Mantel-Cox) test. (b) Body weight of control mice given PBS, heart failure mice given PBS 
and heart failure mice given antimiR-370-3p following TAC surgery (n = 9, 5 and 10). (c) Body weight on day 
of sacrifice of control mice given PBS, control mice given antimiR-370-3p, heart failure mice given PBS and 
heart failure mice given antimiR-370-3p (n = 15, 6, 15 and 10). *P < 0.05; one-way ANOVA followed by Tukey’s 
multiple comparisons test. (d) Typical examples of hearts from a control mouse given PBS, heart failure mouse 
given PBS, and heart failure mouse given antimiR-370-3p. All images shown on the same scale. LA, left atrium; 
LV, left ventricle, RA, right atrium; RV, right ventricle. (e, f) Heart weight (n = 16, 19 and 10) and heart weight to 
tibia length ratio (n = 8, 4 and 10) of the three groups of mice. *P < 0.05; one-way ANOVA followed by Tukey’s 
multiple comparisons test.
▸
3Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11279  | https://doi.org/10.1038/s41598-020-67790-0
www.nature.com/scientificreports/
Control Control+
antimiR
Heart 
failure
Heart failure
+antimiR
0
5
10
15
20
25
30
Bo
dy
 w
ei
gh
t (
g)
**
*
*
Control Heart
failure
Heart failure
+antimiR
0.0
0.1
0.2
0.3
0.4
H
ea
rt 
w
ei
gh
t (
g)
*
*
Control Heart
failure
Heart failure
+antimiR
0.00
0.05
0.10
0.15
0.20
0.25
H
ea
rt 
w
ei
gh
t/t
ib
ia
 le
ng
th
(g
/c
m
)
*
0 10 20 30 40 50
25
27
29
31
Day after TAC surgery
Bo
dy
 w
ei
gh
t (
g)
Heart
failure
Heart failure
+antimiR
Control
antimiR
injection
0 10 20 30 40 50 60
0
20
40
60
80
100
Day after TAC surgery
Su
rv
iv
al
 (%
)
antimiR
injectionTAC
Heart
failure
Heart failure
+antimiR
Control
Control
+antimiR
*
Control Heart failure Heart failure + antimiR
RA
RV LV
LA
2 mm
a
b
d
e f
c
4Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:11279  | https://doi.org/10.1038/s41598-020-67790-0
www.nature.com/scientificreports/
*
Control Heart
failure
Heart failure
+antimiR
0
1
2
3
4
5
LV
ID
s 
(m
m
)
**
Control Heart
failure
Heart failure
+antimiR
0
50
100
150
200
250
Le
ft 
ve
nt
ric
le
 m
as
s 
(m
g)
*
*
*
Control Heart
failure
Heart failure
+antimiR
0
10
20
30
40
Fr
ac
tio
na
l s
ho
rte
ni
ng
 (%
) P=0.052*
Control Heart
failure
Heart failure
+antimiR
0
1
2
3
4
5
LV
ID
d 
(m
m
)
**
*
Control Heart failure Heart failure + antimiRa
b
e
c
d
Figure 2.  Silencing miR-370-3p improves cardiac function in heart failure. (a) Cross section images during 
diastole (all shown on the same scale) and M-mode images (all shown on the same scale) of the left ventricle 
in a control mouse given PBS, heart failure mouse given PBS and heart failure mouse given antimiR-370-3p. 
(b) Mean left ventricle mass (n = 19, 12 and 10). *P < 0.05; Kruskal–Wallis test followed by Dunn’s multiple 
comparisons test. †P < 0.05; Mann–Whitney test. (c–e) Left ventricle inner dimension during diastole (LVIDd; 
n = 19, 13 and 10), inner dimension during systole (LVIDs; n = 19, 13 and 10) and fractional shortening (n = 19, 
13 and 8) in the three groups of mice. *P < 0.05; one-way ANOVA followed by Tukey’s multiple comparisons test.
5Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11279  | https://doi.org/10.1038/s41598-020-67790-0
www.nature.com/scientificreports/
Heart failure produces remodelling of the sinus node. The sinus bradycardia could be the result 
of a remodelling of ion channels and the corresponding ionic currents in the sinus  node10,11,15, or the result of 
fibrosis in the sinus  node14. Tissue biopsies were taken of sinus node as well as atrial and ventricular muscle and 
the expression of a selection of transcripts was measured by quantitative PCR (qPCR). In the sinus node of the 
heart failure mice, of the transcripts targeted, some were significantly upregulated, some unchanged and some 
significantly downregulated (Supplementary Figs.  3 and 4). There are two principal pacemaker mechanisms 
in the sinus node, the membrane clock and the intracellular  Ca2+  clock33. In the sinus node of the heart failure 
mice, there was no change in the mRNA for various components of the intracellular  Ca2+ clock (RyR2, SERCA2, 
calsequestrin and NCX1; Supplementary Figs. 3 and 5) and no change in the mRNA for related  Ca2+ channel 
subunits  (Cav1.2,  Cavα2δ2; Supplementary Fig. 3). These data suggest that there is no change in the sinus node 
intracellular  Ca2+ clock in heart failure (consistent with the findings of Verkerk et al.34). However, this conclusion 
is tentative, because it can be argued that the data may be affected by atrial muscle contaminating the sinus node 
biopsies (although previously we have shown that atrial cell markers are poorly expressed in sinus node biopsies, 
whereas the reverse is true for sinus node  markers35,36). The intracellular  Ca2+ clock is not considered further. 
The most important component of the membrane clock is the funny current (If)37, for which HCN1, HCN2 and 
in particular HCN4 are  responsible38. There was a significant downregulation of mRNA for each of the HCN 
isoforms in the sinus node of the heart failure mice (Fig. 4a–c). Sinus node cells were isolated from control and 
heart failure mice and immunolabelled for HCN4 protein (Fig. 4e) and image analysis showed a statistically sig-
nificant decrease in HCN4 protein immunolabelling in the heart failure mice (Fig. 4f). There should be a corre-
sponding downregulation of If and this was tested using the patch clamp technique and isolated sinus node cells. 
There was a small but significant downregulation in the amplitude of If in heart failure (Supplementary Fig. 6). 
However, in the Supplementary Discussion we argue that the density rather than amplitude of If is important. 
In heart failure, sinus node cells were larger and had a higher capacitance and consequently the downregulation 
in the density of If (Fig. 4g) was larger than the downregulation in amplitude in heart failure (Supplementary 
Fig. 6). This is confirmed by data presented in Fig. 4h, which shows mean current–voltage relationships for If 
density; the decrease was 50% at − 125 mV. To test whether this decrease in If is responsible for the decrease in 
the intrinsic heart rate in heart failure, the intrinsic heart rate (measured in the isolated sinus node) was meas-
ured under baseline conditions and after block of If by 2 mM  Cs+, a relatively specific blocker of If (Fig. 4i)—see 
Supplementary Discussion.  Cs+ decreased the intrinsic heart rate of both control and heart failure mice, but the 
percentage decrease was significantly less in heart failure mice (Fig. 4j), consistent with a downregulation of If in 
heart failure mice. Most importantly, the intrinsic heart rate of the heart failure mice was no longer lower than 
that of the control mice after block of If by  Cs+ (Fig. 4i).
In the sinus node of the heart failure mice, qPCR showed that there was a trend of an upregulation of the 
proinflammatory cytokine, TGFβ1, as well as a significant upregulation of the major collagen isoform in the 
heart, collagen type 1 α1 (Fig. 5a, b). This suggests there was fibrosis of the sinus node in the heart failure mice 
and, therefore, tissue sections through the sinus node were stained with picrosirius red (Fig. 5c), which stains 
collagen 1 and 3 fibres red. Image analysis showed that there was significantly more picrosirius red staining in 
the sinus node of the heart failure mice (Fig. 5d). This demonstrates that there was fibrosis of the sinus node in 
heart failure; a similar fibrosis was also observed in the atrial and ventricular muscle (Supplementary Figs. 7 and 
8). The fibrosis was, therefore, not restricted to the sinus node. Both immunohistochemistry (immunolabelling 
of the cell membrane) and patch clamp experiments (measurement of cell capacitance) showed that there was a 
significant increase in the size of sinus node cells in the heart failure mice (Supplementary Fig. 9), demonstrating 
that there was hypertrophy of the sinus node as well as the rest of the heart (Figs. 1, 2).
Mechanisms underlying the remodelling of the sinus node in heart failure. What is responsible 
for the remodelling of the sinus node, in particular of HCN4, in heart failure? We investigated the role of tran-
scriptional regulators (transcription factors) and post-transcriptional regulators (microRNAs) in defining the 
level of HCN4. HCN4 mRNA levels are regulated by the transcription factors  AP139,  Isl140,41,  Mef2c39, Nkx2.542, 
 NRSF43,  Tbx344 and  Tbx1845; BMP2, BMP4 and Shox2 are sinus node specific transcription  factors46. For exam-
ple, the transcription factors, Tbx3 and Tbx18, are known to control the pacemaking phenotype of the sinus 
node and ectopic expression of Tbx3 and Tbx18 in working myocardium causes an upregulation of HCN4 and 
a switch to a sinus node  phenotype44,45. In the heart failure mice, qPCR showed no significant change in Bmp2, 
Bmp4, Nkx2.5, Shox2 and Tbx3 in the sinus node, but there was a significant downregulation of Tbx18 and Isl1 
and upregulation of AP1, Mef2c and NRSF mRNA (Supplementary Fig. 4).
Expression of 754 rodent microRNAs in the sinus node was determined using a TaqMan Gene Expression 
Assay (ThermoFischer Scientific). Among the 754 microRNAs, 44 microRNAs showed a significant difference 
between control and heart failure mice (Fig. 6a). 24 microRNAs were significantly upregulated in the sinus 
node of the heart failure mice and 20 microRNAs were significantly downregulated (Fig. 6a). Of the upregu-
lated microRNAs, four (miR-139-3p, miR-145-5p, miR-351-3p and miR-370-3p) were identified by Ingenuity 
Pathway Analysis software (Qiagen) as potentially targeting HCN4. RNA22 software predicted that HCN4 has 
10 potential binding sites (two of which are significant) for miR-370-3p, five (two of which are significant) for 
miR-139-3p, two for miR-351-3p and just one for miR-145-5p (Supplementary Table 2). miR-370-3p was the 
subject of further study, although some experiments were also conducted on miR-139-3p (the two microRNAs 
with the greatest number of predicted binding sites). We focussed our investigations on the most common 
isoform of miR-370-3p, as defined by over 70 small RNA deep sequencing datasets in both mouse and human 
catalogued by the miRBase database—see Supplementary Discussion for further information. An independent 
qPCR assay confirmed that miR-370-3p was significantly upregulated in the sinus node in heart failure (Fig. 6b). 
miR-370-3p was also expressed in atrial muscle; there was a trend of upregulation in heart failure, but it was not 
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significant (Supplementary Fig. 10). Expression of miR-370-3p in ventricular muscle was significantly less than 
in the sinus node and, furthermore, it did not respond to heart failure (Fig. 6b). MicroRNAs can be generated 
by cardiomyocytes or associated  fibroblasts47 and, to distinguish between the two sources, expression of miR-
370-3p and HCN4 as a reference was measured in isolated intact sinus node tissue and pure fibroblast populations 
isolated from the sinus node (Supplementary Fig. 11). Expression levels of the transcripts were normalised to 
RNU6. As expected, HCN4 was present in the sinus node, but absent from fibroblasts (Supplementary Fig. 11). 
miR-370-3p showed the same pattern (Supplementary Fig. 11) and this suggests that most miR-370-3p originates 
from sinus node cardiomyocytes.
miR-370 overlaps an intron in a complex set of alternately spliced transcripts from a lincRNA locus (Rian-210 
and Rian-216) in mouse. The same transcripts also appear to express the rodent-specific microRNAs miR-341 
and miR-1188. These three microRNAs may therefore be co-regulated in mouse. In both mouse and human, 
miR-139 is located in an intron of the protein-coding gene Pde2a (phosphodiesterase 2A). Therefore, it is pos-
sible that miR-139-3p and Pde2a are co-regulated, as has been shown previously for other intronic microRNAs 
and their host  genes48,49. It is interesting that upregulation of miR-341, miR-1188 and Pde2a have all been linked 
to cardiac hypertrophy or heart  failure50–52. Although no change in miR-1188-3p was observed in the present 
study (data not shown; miR-341 not investigated), qPCR showed evidence of upregulation of Pde2a mRNA in 
the sinus node, but not ventricle, in heart failure (Supplementary Fig. 12a).
miR‑370‑3p is also upregulated in the human sinus node in heart failure. The sequence of miR-
370-3p is perfectly conserved across many species including human, rat and mouse (Supplementary Fig. 13; the 
same is true of miR-139-3p—Supplementary Fig. 14). Experiments were conducted on the healthy sinus node 
from three human subjects and the sinus node from five heart failure patients to determine whether miR-370-3p 
is also upregulated in the human sinus node in heart failure (details of human subjects given in Supplementary 
Table 3). There was an upregulation of miR-370-3p in the heart failure group (Fig. 6c). The General Linear Model 
was used to evaluate the statistical significance of the difference in miR-370-3p between hearts with and without 
heart failure. After adjusting for other factors, including gender, age, heart weight and diabetes mellitus status, 
the effect of heart failure was statistically significant (P < 0.001).
HCN4 is a target of miR‑370‑3p (and miR‑139‑3p). The two significant potential binding sites for 
miR-370-3p within mouse HCN4 mRNA are in the mRNA corresponding to exons 2 and 8 and are shown in 
Fig. 7a (exon 2 site) and Supplementary Fig. 15 (exon 8 site). The predicted binding sites for miR-370-3p are 
in the coding region—recent evidence suggests that microRNA target sites in the coding region may be just as 
important as those in 3′-UTR 53. Luciferase reporter gene assays were carried out to test whether the predicted 
binding sites are functionally important: mRNA corresponding to exon 2 (or exon 8) was inserted as the 3′-UTR 
of the luc2 firefly luciferase gene (constitutively active under the control of the phosphoglycerate kinase 1 pro-
moter; Fig.  7b). The plasmid was transfected into H9C2 cells with or without plasmid expressing precursor 
miR-370. miR-370-3p significantly reduced luciferase activity (luciferase bioluminescence normalised to Renilla 
bioluminescence; surrogate of HCN4) with exon 2 of HCN4, but not with exon 8 of HCN4 (Fig. 7c). Mutation of 
the predicted miR-370-3p binding sequence in exon 2 abolished the effect of miR-370-3p on luciferase activity; 
mutation of the potential binding sequence in exon 8 had no effect (Fig. 7c). This finding demonstrates a specific 
interaction between miR-370-3p and HCN4, and the predicted recognition element identified in the exon 2 of 
HCN4 contributes to this.
The predicted binding sites for miR-139-3p were not investigated. However, using a luciferase reporter gene 
assay with the 3′-UTR of HCN4 cloned downstream of the luciferase gene, we have previously screened various 
microRNAs, including miR-139-3p, for effects mediated by the 3′-UTR of  HCN454. miR-139-3p significantly 
decreased luciferase activity (Supplementary Fig. 12b); this demonstrates a specific interaction between miR-
139-3p and HCN4.
Ingenuity Pathway Analysis identified other ion channels as potential targets of miR-370-3p, but none were 
significantly changed at the transcript level during heart failure (Supplementary Fig. 16). However, it is known 
that microRNAs can operate at the level of protein translation without producing corresponding changes in 
steady state mRNA  levels55 and this possibility cannot be excluded.
Overexpression of miR‑370‑3p (and miR‑139‑3p) induces bradycardia. To test whether overex-
pression of miR-370-3p can produce bradycardia, we transfected isolated sinus node preparations (Fig. 8a) with 
miR-370-3p. 1–2 μl of 10 nM double-stranded synthetic miR-370-3p (together with Lipofectamine Transfection 
Figure 3.  Silencing miR-370-3p improves ECG parameters in heart failure. (a) Heart rate (measured in 
conscious animals) of control mice given PBS, heart failure mice given PBS and heart failure mice given 
antimiR-370-3p following TAC surgery (n = 13, 13 and 17). (b) Heart rate (measured in conscious animals) of 
the three groups of mice on the day of sacrifice (n = 8, 9 and 16). *P < 0.05; one-way ANOVA followed by Tukey’s 
multiple comparisons test. (c–f) PR interval (n = 13, 10 and 8), QRS duration (n = 9, 14 and 9), QT interval 
(n = 9, 14 and 9) and corrected QT interval (n = 9, 14 and 9) of the three groups of mice on the day of sacrifice 
(measured in anaesthetised animals). *P < 0.05; one-way ANOVA followed by Tukey’s multiple comparisons test. 
(g) Intrinsic heart rate (measured from the isolated sinus node preparation) of the three groups of mice (n = 8, 
11 and 13). *P < 0.05; one-way ANOVA followed by Holm-Sidak’s test (one comparison only). The difference 
between heart failure and heart failure + antimir was tested using Student’s unpaired t test (P value given).
▸
7Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11279  | https://doi.org/10.1038/s41598-020-67790-0
www.nature.com/scientificreports/
20 30 40 50
680
720
760
800
Day after TAC surgery
He
ar
t r
at
e 
(b
ea
ts
/m
in
)
Heart
failure
Heart failure
+antimiR
Control
antimiR
injection
*
Control Heart
failure
Heart failure
+antimiR
0
10
20
30
40
PR
 in
te
rv
al
 (m
s)
**
Control Heart
failure
Heart failure
+antimiR
0
10
20
30
40
Q
T 
in
te
rv
al
 (m
s)
*P=0.086
Anaesthetised mouse
Control Heart
failure
Heart failure
+antimiR
650
700
750
800
He
ar
t r
at
e 
(b
ea
ts
/m
in
) **
*
Control Heart
failure
Heart failure
+antimiR
0
5
10
15
20
Q
RS
 d
ur
at
io
n 
(m
s) *
*
Control Heart
failure
Heart failure
+antimiR
0
20
40
60
80
100
Q
T(
c)
 in
te
rv
al
 (m
s)
**
Conscious mouse
Isolated sinus node
a
c
e
g
f
b
d
*
Control Heart
failure
Heart failure
+antimiR
340
360
380
400
420
440
In
tri
ns
ic
 b
ea
tin
g
ra
te
 (b
ea
ts
/m
in
)
P=0.061
8Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:11279  | https://doi.org/10.1038/s41598-020-67790-0
www.nature.com/scientificreports/
**
*
-120 -100 -80 -60 -40 -20
-35
-30
-25
-20
-15
-10
-5
0
mV
If  (pA/pF)Heart failure
+antimiR
Control
Heart
failure
Control
+antimiR
*
*
Control Control
+antimiR
Heart
failure
Heart
failure
+antimiR
0
20
40
60
80
HC
N4
 p
ro
te
in
 (a
u)
*
Baseline Cs+
250
300
350
400
In
tri
ns
ic
 h
ea
rt 
ra
te
(b
ea
ts
/m
in
)
P=
0.061*
Control Heart
failure
Heart failure
+antimiR
0
10
20
30
40
Ch
an
ge
 o
f i
nt
rin
si
c
he
ar
t r
at
e 
w
ith
 C
s 
(%
) *
i
*
Sinus
node
Atrial
muscle
Ventricular
muscle
0
2 10-5
4 10-5
6 10-5
8 10-5
1 10-4
HC
N1
 m
RN
A *
*
Sinus
node
Atrial
muscle
Ventricular
muscle
0
1 10-5
2 10-5
3 10-5
4 10-5
HC
N2
 m
RN
A
*
Sinus
node
Atrial
muscle
Ventricular
muscle
0
2 10-5
4 10-5
6 10-5
8 10-5
1 10-4
HC
N4
 m
RN
A
Control Heart
failure
Heart failure
+antimiR
0
2 10-4
4 10-4
6 10-4
HC
N4
 m
RN
A
*a b c
e
f
g
h
d
j
Control
Heart failure
Heart failure
+antimiR
Control
Heart failure
20 m
Heart failure
+antimiR
2 s
20
 p
A/
pF
Figure 4.  Silencing miR-370-3p improves functioning of the sinus node in heart failure. (a–c) Expression of 
mRNA for HCN1 (a; n = 7, 8, 6, 10, 6 and 10), HCN2 (b; n = 7, 8, 6, 10, 6 and 10) and HCN4 (c; n = 7, 8, 5, 9, 6 
and 9) in the sinus node, atrial muscle and ventricular muscle of control and heart failure mice. *P < 0.05; one-
way ANOVA followed by Sidak’s multiple comparisons test. (d) Expression of HCN4 mRNA in the sinus node 
of control mice given PBS, heart failure mice given PBS and heart failure mice given antimiR-370-3p (n = 14, 8 
and 10). *P < 0.05; Kruskal–Wallis test followed by Dunn’s multiple comparisons test. †P < 0.05; Mann–Whitney 
test. (e) Sinus node cells from the three types of mouse immunolabelled for HCN4. All images at the same 
scale. (f) Mean intensity of immunolabelling of HCN4 in sinus node cells from control mice given PBS, control 
mice given antimiR-370-3p, heart failure mice given PBS and heart failure mice given antimiR-370-3p (n = 26, 
40, 39 and 22 cells). *P < 0.05; Kruskal–Wallis test followed by Dunn’s multiple comparisons test. (g) Families 
of recordings of If from sinus node cells from control mice given PBS, heart failure mice given PBS and heart 
failure mice given antimiR-370-3p. (h) Mean current–voltage relationships for If from sinus node cells from 
control mice given PBS, control mice given antimiR-370-3p, heart failure mice given PBS and heart failure mice 
given antimiR-370-3p (n = 11, 43, 40 and 46 cells). *P < 0.05; significant differences between heart failure mice 
given PBS and (1) control mice given PBS, (2) heart failure mice given antimiR-370-3p and (3) control mice 
given antimiR-370-3p; other significant differences are not shown for clarity. (i) Intrinsic heart rate (measured 
from the isolated sinus node preparation) of control mice given PBS, heart failure mice given PBS and heart 
failure mice given antimiR-370-3p under baseline conditions (same data as in Fig. 3g) and in the presence of 
2 mM  Cs+ to block If; see Fig. 3g legend for n numbers and meaning of symbols. (j) Percentage change in the 
intrinsic heart rate of control mice given PBS, heart failure mice given PBS and heart failure mice given antimiR-
370-3p on the addition of 2 mM  Cs+ (n = 16, 15 and 14). *P < 0.05; one-way ANOVA followed by Tukey’s 
multiple comparisons test.
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10, 6 and 10). *P < 0.05; Kruskal–Wallis test followed by Dunn’s multiple comparisons test. †P < 0.05; Student’s 
unpaired t test. (c) Images of picrosirius red stained tissue sections (all at same scale) through the sinus node of 
a control mouse given PBS, a heart failure mouse given PBS and a heart failure mouse given antimiR-370-3p. 
Red stain, collagen; yellow stain, cardiac myocytes. (d) Mean intensity of picrosirius red staining of collagen 
(red signal) in the three groups of mice (n = 29, 35 and 47 sections from n = 4, 3 and 3 mice). *P < 0.05; one-way 
ANOVA followed by Tukey’s multiple comparisons test. (e) Expression of collagen type 1 α1 mRNA in the three 
groups of mice (n = 7, 8 and 8). *P < 0.05; one-way ANOVA followed by Tukey’s multiple comparisons test.
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expression in control mice. The dotted line shows the control level. Based on data from 8 control and 10 heart 
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of miR-370-3p in the sinus node of control and heart failure patients (n = 3 and 5). *P < 0.05; after adjusting for 
effects of other factors and normalising differences between experiments, the General Linear Model was used to 
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Reagent) was injected into the centre of the sinus node at the bifurcation of the sinus node artery using a 35G 
needle (Fig. 8a). This series of experiments was conducted on sinus node preparations isolated from the rat, 
because injection into the smaller mouse preparations was not feasible. However, miR-370-3p is conserved in 
human, rat and mouse (Supplementary Fig. 13) and in all three species miR-370-3p is highly predicted to affect 
HCN4 by Ingenuity Pathway Analysis software (Qiagen). To serve as a control, other sinus node preparations 
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Figure 7.  miR-370-3p regulates HCN4. (a) Predicted miR-370-3p binding site in exon 2 of HCN4. In the 
mutant, the predicted exon 2 binding site was mutated from AUC AUC CUUG ACC CGC AGA GGA (wild-type) 
to AUC AUC CUUG CAA CGC AGA GGA (mutant)—the corresponding nucleotides are in bold. (b) Luciferase 
reporter gene construct. PGK, phosphoglycerate kinase 1. (c) Luciferase reporter assay showing effect of miR-
370-3p on HCN4. Effects mediated by potential binding sites in exons 2 (left) and 8 (right) were investigated. 
Bars show luciferase activity (surrogate of HCN4) when: miR-370-3p was incubated with the wild-type exon; 
miR-370-3p was incubated with a mutant exon (potential binding site mutated); and wild-type exon was 
not exposed to miR-370-3p. Luciferase activity is shown 24 h after co-transfection. Exon 2, n = 14, 10 and 5 
measurements; exon 8, n = 7, 6 and 7 measurements. Exon 2: *P < 0.05, Kruskal–Wallis test followed by Dunn’s 
multiple comparisons test; in addition, the Mann–Whitney test was used to test the difference between miR-
370-3p + HCN4 exon 2 and control (HCN4 exon 2 only) and the P value is shown. Exon 8: one-way ANOVA 
revealed no significant differences.
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were transfected with a scrambled (non-targeting) microRNA, designed to have no sequence similarity to any 
known microRNA sequence in the database. Injected preparations were maintained in tissue culture. qPCR 
showed a 207% upregulation of miR-370-3p 28–42 h after injection (P = 0.080; Fig. 8b). Overexpression of miR-
370-3p resulted in a significant decrease in the beating rate of the sinus node preparations (in comparison to 
the beating rate of preparations injected with a scrambled microRNA) and this effect possibly started ~ 5 h after 
injection of miR-370-3p (Fig.  8c). Tissue sections cut through the sinus node 28–42  h after injection of the 
preparations with miR-370-3p or the scrambled microRNA were immunolabelled for HCN4 (Fig. 8d); image 
analysis showed a significantly lower expression of HCN4 protein in the sinus node in preparations overexpress-
ing miR-370-3p (Fig. 8e). In another series of experiments, isolated mouse sinus node cells were incubated with 
10 nM miR-370-3p or 10 nM scrambled microRNA for 4–6 h and then If was recorded with the patch clamp 
technique (Fig. 8f). Experiments were carried out on mice of the same strain (C57BL6/N) and age as the mice 
used to generate the heart failure model. Figure 8g shows mean current–voltage relationships for If density and 
it shows that incubation with miR-370-3p resulted in a significant decrease in the density of If. Taken together, 
these data show that miR-370-3p causes a bradycardia probably by downregulating HCN4 and thus If.
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Figure 8.  miR-370-3p regulates HCN4 and If density. (a) Isolated sinus node preparation showing the 
bifurcation of the sinus node artery where microRNA was injected. CT, crista terminalis; SVC, superior vena 
cava. (b) Expression of miR-370-3p 28–42 h after the injection of isolated sinus node preparations with a 
scrambled microRNA or miR-370-3p (n = 9 and 9). Data analysed using Student’s unpaired t test and P value 
given. (c) Time course of the beating rate of isolated sinus node preparations following the injection of a 
scrambled microRNA or miR-370-3p (n = 9 and 9). *P < 0.05; two-way ANOVA followed by Sidak’s multiple 
comparisons test. (d) Immunolabelling of HCN4 in tissue sections (shown at same scale) through the sinus 
node of isolated sinus node preparations that had been injected with a scrambled microRNA or miR-370-3p 
28–42 h previously. (e) Mean intensity of immunolabelling of HCN4 in the sinus node of isolated sinus node 
preparations that had been injected with a scrambled microRNA or miR-370-3p 28–42 h previously (n = 2 and 
3). (f) Families of recordings of If from sinus node cells that had been incubated with a scrambled microRNA or 
miR-370-3p for 6 h. (g) Mean current–voltage relationships for If from sinus node cells that had been incubated 
with a scrambled microRNA or miR-370-3p for 6 h (n = 4 and 14). *P < 0.05; two-way ANOVA followed by 
Sidak’s multiple comparisons test.
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Injection of miR-139-3p into isolated sinus node preparations also resulted in a bradycardia from 8 h after 
injection (Supplementary Fig. 12c). 24 h after injection, immunohistochemistry showed a significant decrease 
in HCN4 protein expression in the sinus node (Supplementary Fig. 12d).
Silencing of miR‑370‑3p in heart failure partially restores sinus node function. If the upregula-
tion of miR-370-3p in heart failure is responsible for the sinus node dysfunction, silencing miR-370-3p should 
benefit the sinus node. To test this, mice were treated with antimiR-370-3p from 21 days after TAC surgery. 
AntimiRs are antisense oligonucleotides modified to enhance duplex stability and have been used effectively to 
inhibit microRNA function in vitro and in vivo56,57. From 21 days after TAC surgery, mice were given a daily 
dose of antimiR (20 mg/kg) in phosphate buffered saline (PBS) for 3 days followed by a weekly dose for 3 weeks. 
Two control groups (sham-operated mice and mice subjected to TAC) did not receive the antimiR—both control 
groups were given the vehicle (PBS) only. There were two other control groups: sham-operated mice were given 
antimiR or the scrambled antimiR (20 mg/kg in PBS). The mice were sacrificed ≤ 60 days after surgery. AntimiR-
370-3p injection decreased miR-370-3p levels in the sinus node of heart failure mice as compared to heart failure 
mice which only received an injection of PBS; the level was decreased to below that in the sham-operated mice 
(Fig. 6b). AntimiR-370-3p had many general beneficial effects for the heart failure mice. The most striking was 
that survival of the heart failure mice was significantly improved (P = 0.013, log-rank test): 15 out of 15 sham-
operated mice survived, 17 out of 20 heart failure mice which received antimiR-370-3p survived, whereas only 6 
out of 17 heart failure mice which received PBS only survived (Fig. 1a). AntimiR-370-3p restored body weight to 
control values (Fig. 1b, c). However, heart weight (Fig. 1e) and heart weight to tibia length ratio and heart weight 
to body weight ratio (Fig. 1f; Supplementary Fig. 1a) only showed a trend towards restoration. Echocardiography 
revealed improvements in cardiac function of heart failure mice after injection of antimiR-370-3p: left ventricle 
mass and internal diameter in diastole and systole were all significantly decreased towards normal, and left ven-
tricle fractional shortening was increased towards normal (P = 0.052; Fig. 2).
In heart failure mice, antimiR-370-3p restored the heart rate measured in the unrestrained conscious mouse 
towards normal (Fig. 3a, b). It also restored the intrinsic beating rate of the isolated sinus node preparation 
(Fig. 3g) towards normal (the beating rate is no longer significantly different from the control). This is the first 
evidence that antimiR-370-3p protects the sinus node from the effects of heart failure. AntimiR-370-3p also 
reversed the first-degree heart block, i.e. prolongation of the PR interval (Fig. 3c). This suggests that antimiR-
370-3p also protects the atrioventricular node from the effects of heart failure. This is not surprising, because 
the two nodes share much in  common29. However, antimiR-370-3p did not reverse the effects of heart failure on 
the His-Purkinje system: it did not restore the QRS duration (Fig. 3d). However, antimiR-370-3p did restore the 
QT and corrected QT intervals to normal (Fig. 3e, f), which is another indicator that the severity of heart failure 
was reduced. There was other evidence that antimiR-370-3p protected the sinus node from the effects of heart 
failure. AntimiR-370-3p significantly restored HCN4 mRNA beyond control (Fig. 4d), HCN4 protein to control 
(Fig. 4e, f), and If density towards control (Fig. 4g, h). The responsiveness of the isolated sinus node to  Cs+ block 
of If was also increased towards control (the responsiveness was no longer significantly different from the control; 
Fig. 4j). Why HCN4 mRNA but not the other measures should rebound beyond the control level is not known. 
Finally, antimiR-370-3p also partially reversed the hypertrophy of sinus node cells (Supplementary Fig. 9).
Figure 5d, e shows that antimiR-370-3p largely prevented fibrosis of the sinus node in heart failure: picrosirius 
red staining was significantly restored towards normal and collagen type 1 α1 mRNA was significantly restored 
to normal. AntimiR-370-3p also significantly reduced fibrosis in the atrial and ventricular muscle in heart failure 
(Supplementary Figs. 7 and 8).
In the further control experiments on sham-operated mice, the antimir had no effects (as compared to 
sham-operated mice receiving PBS alone) on echocardiography parameters including heart rate (Supplementary 
Table 4), and the scrambled antimiR had little or no effect on mortality, body weight, HCN4 expression or If 
density (Figs. 1a, c, 4f, h).
Discussion
For the first time, this study has shown that the sinus and atrioventricular node dysfunction in heart failure can be 
moderated or reversed by administration of an antimiR. This has important novel clinical implications, because 
bradyarrhythmias (a consequence of sinus node and atrioventricular node dysfunction) are linked to ~ 50% of 
deaths of heart failure  patients6–8. The CARISMA study showed that, in post-myocardial infarction (MI) patients 
with heart failure, sinus and atrioventricular node dysfunction (as indicated by sinus bradycardia and intermit-
tent high-degree atrioventricular block, respectively) are associated with a very high risk of cardiac  death58.
We have shown that in the mouse TAC model of heart failure there is hypertrophy and dilatation of the heart 
and a decrease in the left ventricle fractional shortening, body weight and survival as expected (Figs. 1, 2). There 
is also evidence of dysfunction of the sinus node (bradycardia), atrioventricular node (first-degree heart block) 
and His-Purkinje system (increase in QRS duration) in the heart failure model (Fig. 3) as expected—all these 
changes are observed in heart failure patients e.g.13,59,60. The data suggests that the sinus node dysfunction is the 
result of a downregulation of HCN4 mRNA and protein and subsequently the density of If (Fig. 4). There was 
no evidence of involvement of the  Ca2+ clock in heart failure: there were no significant changes in  Ca2+ clock 
transcripts in the sinus node in heart failure and no significant changes in selected  Ca2+ clock transcripts follow-
ing antimiR-370-3p (Supplementary Fig. 5). Verkerk et al.34 recently concluded that  Ca2+ cycling properties are 
conserved despite bradycardic effects of heart failure in sinus node cells (rabbit model of pressure and volume 
overload studied). On the other hand, Shinohara et al.61 found that heart failure (induced by rapid ventricular 
pacing) results in  Ca2+ clock malfunction in the sinus node of dogs. There was measurable fibrosis in the sinus 
node in heart failure (Fig. 5) consistent with other  work14. Increased extracellular matrix deposition within the 
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sinus node has been shown to disrupt electrical coupling between nodal cells that can result in slowed impulse 
propagation, sinus node exit block and sinus  pauses62. The possibility that the observed increase in fibrosis 
plays a role in sinus node dysfunction in heart failure cannot be excluded, although, in the isolated sinus node, 
injection of miR-370-3p perhaps began to slow pacemaking after 5 h (Fig. 8c) and this is likely to be too short 
for significant fibrosis.
We have shown a widespread dysregulation of transcription factors and microRNAs in the sinus node in heart 
failure (Supplementary Fig. 4; Fig. 6). Of the transcription factors known or predicted to regulate HCN4 (AP1, Isl1, 
Mef2c, Nkx2.5, NRSF, Tbx3 and Tbx18), two (Nkx2.5 and Tbx3) did not change in the sinus node in heart failure 
(Supplementary Fig. 4). HCN4 is a direct transcriptional target of AP1 and  Mef2c39, but these transcription factors 
were significantly upregulated in the sinus node in heart failure (Supplementary Fig. 4) and cannot explain the 
downregulation of HCN4. However, NRSF is potentially involved: NRSF was significantly upregulated in the sinus 
node in heart failure (Supplementary Fig. 4); NRSF is a transcriptional repressor and binds to a silencer element 
within an intron of HCN4 and prevents its  transcription43. Isl1 and Tbx18 are also potentially involved: both Isl1 
and Tbx18 were significantly downregulated in the sinus node in heart failure (Supplementary Fig. 4) and down-
regulation of Isl1 has been shown to downregulate  HCN440,41 and Tbx18 has been shown to upregulate  HCN445; 
however, Tbx18 is a transcriptional  repressor63 and is unlikely to affect HCN4 directly. We observed significant 
changes in 44 microRNAs (Fig. 6), of which five potentially target HCN4, although only four of these were upregu-
lated—appropriate to explain the downregulation of HCN4 (Supplementary Table 2). Of these four, miR-370-3p 
and miR-139-3p had the greatest number of potential binding sites on HCN4 (Supplementary Table 2). Using a 
luciferase reporter assay, both microRNAs were shown to be capable of regulating HCN4 (Fig. 7 and Supplementary 
Fig. 12b). Both microRNAs, when overexpressed in the isolated sinus node, downregulated HCN4 and slowed 
sinus node pacemaking (Fig. 8c–e and Supplementary Fig. 12c, d). In single sinus node cells, miR-370-3p was also 
shown to downregulate If density (Fig. 8f, g). In summary, we have identified five factors that could be involved in 
the downregulation of HCN4 in the sinus node in heart failure: Isl1, NRSF, Tbx18, miR-139-3p and miR-370-3p.
miR-370-3p was the subject of further study. In the sinus node in heart failure, silencing of miR-370-3p by 
antimiR-370-3p blunted or reversed the downregulation of HCN4 mRNA and protein and the density of If; 
antimiR-370-3p also blunted the bradycardia in vivo (Figs. 3, 4). These data suggest that antimiR-370-3p protects 
the sinus node in heart failure. AntimiR-370-3p also reversed the prolongation of the PR interval in heart failure 
(Fig. 3c) and this suggests that antimiR-370-3p also protects the atrioventricular node in heart failure; this is 
not surprising, because the sinus and atrioventricular nodes are similar in terms of embryology, ion channel 
expression and  electrophysiology29. Heart failure resulted in a prolongation of the QRS complex (Fig. 3d), char-
acteristic of heart failure  patients29. We attribute this to slowed conduction through the His-Purkinje system, 
although theoretically it could be the result of fibrosis within the ventricles. However, antimiR-370-3p reversed 
ventricular fibrosis in heart failure (Supplementary Fig. 8), but it did not restore the QRS duration to baseline 
values (Fig. 3d), and this suggest that miR-370-3p-independent electrical remodelling within the His-Purkinje 
system may be the dominant underlying mechanism of QRS prolongation in this model.
Other actions of antimiR‑370‑3p. AntimiR-370-3p also reversed fibrosis in the sinus node (Fig. 5), atrial 
muscle (Supplementary Fig. 7) and ventricular muscle (Supplementary Fig. 8) in heart failure. However, this is 
unlikely to be a direct action of antimiR-370-3p. First, although miR-370-3p is expressed in atrial muscle, it was 
not significantly upregulated in heart failure (Supplementary Fig. 10), and miR-370-3p is poorly expressed in 
ventricular muscle where it was unresponsive to heart failure and antimiR-370-3p (Fig. 6b). Secondly, miR-370 
has been reported to be anti-fibrotic in  heart64 and  liver65. In relation to fibrosis and hypertrophy in angiotensin 
II-induced cardiac hypertrophy, Bang et al.66 demonstrated that microRNA can be secreted by cardiac fibroblasts 
in exosomes and exert a paracrine action on cardiac myocytes. However, Yuan and  Gao64 showed that exposure 
of cultured neonatal rat cardiac fibroblasts to angiotensin II for 24 h resulted in a downregulation of miR-370 
(as well as an upregulation of TGFβ1 and TGFβRII). Yuan and  Gao64 showed that TGFβRII is a target of miR-
370 and concluded miR-370 is anti-fibrotic. The experiment shown in Supplementary Fig. 11 suggests that the 
majority of miR-370-3p is expressed in the cardiomyocytes of the sinus node.
Antimir-370-3p also partially reversed hypertrophy of sinus node cells (Supplementary Fig. 9) and ventricular 
hypertrophy and dilatation (Figs. 1, 2). However, again this is unlikely to be a direct action of antimiR-370-3p. 
Although miR-370-3p potentially targets transcripts linked to cardiac hypertrophy (Supplementary Table 5), 
once again the problem is the poor expression of miR-370-3p in ventricular muscle and its unresponsiveness to 
heart failure (Fig. 6b). Finally, antimiR-370-3p partially rescued ventricular function, largely prevented the loss 
of body weight and reduced mortality (Figs. 1, 2). These are likely to be indirect actions of antimiR-370-3p: the 
improvement in ventricular function is likely to be a consequence of the improvement in ventricular fibrosis and 
hypertrophy, and the improvement in body weight and mortality is likely to be a consequence of the improve-
ment in ventricular function. If the improvement in ventricular fibrosis and hypertrophy are not the result of a 
direct action of antimiR-370-3p on the ventricles, what is responsible? One possibility is that the improvement 
in ventricular fibrosis and hypertrophy is an indirect consequence of an unknown action of antimiR-370-3p 
on another organ (an off-target effect). For example, miR-370-3p has been previously reported to control lipid 
metabolism and to lead to an accumulation of triglycerides in the  liver67.
Working hypothesis. Figure 9 summarises events in heart failure (well established in black, established by 
this study in red and conjectural in grey). It is well established that in mild heart failure (as shown by the inner 
loop in black in Fig. 9), there is activation of the sympathetic nervous system resulting in an increase in heart 
 rate2,68. This is despite the fact that there may be some underlying dysfunction of the sinus node and a decrease in 
the intrinsic heart  rate2,9,13. There is consensus that a high heart rate will worsen heart  failure4, which is a reason 
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why the cardiologist will reduce the heart rate by prescribing a β-blocker or  ivabradine4,5. However, in end-stage 
heart failure (as shown by the part of the outer loop in red in Fig. 9), we propose the sinus node dysfunction 
becomes more severe and the sinus node can no longer be supported by activation of the sympathetic nervous 
system. This may result in bradycardia in the mouse (Fig. 3) and also in the human: in the CARSIMA study, the 
heart rhythm of 297 post-MI heart failure (ejection fraction < 40%) patients were monitored over two years using 
implantable loop recorders and there was a 7% incidence of sinus bradycardia (≤ 30 beats/min lasting ≥ 8 s) and 
a 5% incidence of sinus arrest (≥ 5 s) as well as a 10% incidence of high-degree atrioventricular block (≤ 30 beats/
min lasting 8 s)58. The sinus node dysfunction may also be responsible for chronotropic incompetence (inability 
of the heart rate to increase commensurate with increased activity, well known in heart  failure2,69). The preva-
lence of chronotropic incompetence in chronic heart failure is high, approaching 70% of  patients70. While the 
mechanism of chronotropic incompetence has previously been attributed to downregulation of beta-receptors 
and desensitization in the presence of increased circulating catecholamine  levels71–73, more recent evidence sug-
gests that reduced sinus node reserve (i.e. sinus node dysfunction) may be  responsible13,69. The possible link of 
chronotropic incompetence to sinus node dysfunction is shown in grey (i.e. as conjectural) in Fig. 9. This study 
shows that the sinus node dysfunction (and perhaps the atrioventricular node dysfunction) is the result of an 
upregulation of miR-370-3p (and perhaps miR-139-3p), downregulation of HCN4 and downregulation of If 
(Fig. 9). We propose that the nodal dysfunction in heart failure should not be ignored and instead be treated and 
perhaps an antimiR offers a suitable means as shown by this proof-of-principle study.
The cause of the upregulation of miR-370-3p (and perhaps miR-139-3p) is outside the scope of this study. 
However, the effect of the beta blocker, bisoprolol, in heart failure on the sinus node has been investigated by Du 
et al.74 in the rat and, interestingly, it partially reverses the sinus bradycardia and sinus node dysfunction and it 
fully reverses the downregulation of HCN4. This suggests that the remodelling may be due to the hyperadrenergic 
state seen in chronic heart  failure74.
The partial rescue of ventricular function, body weight and mortality by antimiR-370-3p (Figs. 1, 2) could 
be an off-target effect (shown in grey, i.e. as conjectural, in Fig. 9) as explained above. However, an alternative 
explanation is that the sinus (and atrioventricular) node dysfunction in heart failure worsens heart failure by 
causing a ‘bradycardiomyopathy’ (again shown in grey, i.e. as conjectural, in Fig. 9). It has been shown that the 
development of bradycardia can lead to new symptoms of heart failure and decompensation of pre-existing 
heart  failure75–84. The effect of heart rate can be tentatively estimated: during heart failure, the mean heart rate 
decreased from ~ 795 to ~ 681 beats/min (Fig. 3a) and the mean stroke volume decreased from 71.1 to 55.5 μl 
(Supplementary Table 1; this assumes that the stroke volume in the conscious mouse behaves in the same manner 
Figure 9.  Working hypothesis: relationship between heart failure and sinus node dysfunction. The inner loop 
(in black) is well known. Treatment of heart failure patients with β-blockers or ivabradine reduces the heart 
rate, which is considered beneficial. The outer loop (in red) explains the data in this study. Conjecture as to why 
antimiR-370-3p should lessen heart failure and improve mortality in the mouse is shown in grey: either it has 
off-target effects, which lessen heart failure etc., or by improving sinus node function, it lessens heart failure etc. 
(possibly by relieving chronotropic incompetence and bradycardiomyopathy).
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as the stroke volume in the anaesthetised mouse). The decrease of the stroke volume alone will decrease cardiac 
output by ~ 22%, whereas the decrease of heart rate alone will decrease cardiac output by ~ 14%; the effect of heart 
rate is, therefore, tentatively predicted to be considerable. In addition, PR prolongation (causing atrioventricular 
delay) is associated with diastolic mitral regurgitation and decreased stroke  volume85,86. In this scenario, antimiR-
370-3p, by relieving sinus node dysfunction (and also atrioventricular node dysfunction) in heart failure, will 
indirectly improve ventricular fibrosis, hypertrophy, dilatation and function and, consequently, body weight 
and mortality. It is perhaps pertinent that antimiR-370-3p failed to improve the stroke volume (Supplementary 
Fig. 1). Therefore, any improvement in cardiac output would have been the result of the improvement in the 
heart rate (Fig. 3a, b).
Methods
Heart failure model. Care and use of laboratory animals conformed to the UK Animals (Scientific Pro-
cedures) Act 1986 and Directive 2010/63/EU of the European Parliament. Ethical approval for all experimental 
procedures was granted by the University of Manchester Animal Welfare and Ethical Review body. Male mice 
(C56BL/6N strain) of 8–9 weeks of age (25–30 g) were used. All TAC procedures were carried out as described 
 previously87 and performed by the same experienced operator who was blinded to animal details. The animals 
were anaesthetised with inhalation isoflurane (2–3%). The mice were ventilated with a tidal volume of 0.13 ml 
and a respiratory rate of 110 breaths per minute (Harvard Apparatus). A longitudinal incision of 2–3 mm was 
made in the proximal sternum to allow visualisation of the aortic arch. The transverse aortic arch was ligated 
with three knots using a 7–0 prolene suture between the innominate and left common carotid arteries with an 
overlaid 27-gauge needle. The needle was then removed, leaving a discrete region of constriction to maintain a 
pressure gradient of about 35–50 mm Hg between the left and right carotid arteries. For the sham procedure, 
the aortic arch was isolated and entwined with a 7–0 prolene suture without ligation. Heart rate and body weight 
of the mice were measured approximately every week. Mice were sacrificed by cervical dislocation when they 
showed symptoms of heart failure (loss of the normal lustre of the fur, rapid breathing, weakness, lack of move-
ment and, most importantly, loss of more than 20% of body weight).
AntimiR administration. AntimiR-370-3p (targeting the short form of miR-370-3p; product code 
199,900), was purchased from Exiqon. Exiqon antimiRs use locked nucleic acid technology and have been 
widely used in other studies e.g. 88. AntimiR-370-3p was diluted with sterile PBS (catalogue no. J611196, Alfa 
Aesar) following the recommendations of the manufacturer. All solutions were mixed by vortexing for 10  s 
and incubated for at least 15 min at 37 °C before injection. Each mouse received antimiR (20 mg kg−1) through 
intraperitoneal injection consecutively for three days (3 weeks after TAC surgery) and three additional injections 
were performed once a week for the following 3 weeks; a similar dosing procedure has been used  previously89. 
Other mice received an injection of PBS without added antimiR. All injections were carried out using a 30-gauge 
needle syringe.
ECG recording from conscious mice. ECGs were recorded non-invasively in mice using the ECGenie 
recording enclosure (Mouse Specifics). The ECGenie system comprises a platform with embedded paw-sized 
electrodes connected to an amplifier (e-MOUSE). Signals were collected and analysed using PowerLab and Lab-
Chart (ADInstruments, version 7). Each mouse was acclimatised to the setup for 10 min before data collection. 
Only data from continuous recordings were used in the analysis. A peak detection algorithm on LabChart ena-
bled R-wave identification using Fourier analysis and linear time-invariant digital filtering of frequencies below 
3 Hz and above 100 Hz to minimise environmental signal disturbances. An example of the use of the algorithm 
is shown in Supplementary Fig. 17. The heart rate of healthy conscious mice measured using the ECGenie sys-
tem in this study was ~ 760 beats/min (Fig. 3a). This is within the range of reported heart rates in mice (310–840 
beats/min; https ://web.jhu.edu/anima lcare /proce dures /mouse .html).
ECG recording from anaesthetised mice. Anaesthesia was induced in mice with 2% isoflurane (Isoflo, 
Portugal) in 100%  O2 with a delivery rate of 2 l min−1 until loss of the righting reflex. After induction, the animals 
were moved to a homoeothermic blanket and placed in dorsal recumbence. Anaesthesia was then maintained 
with isoflurane in 100%  O2 with a flow of 1.5 l min−1 administered by means of a facemask connected to a coaxial 
circuit (Fluovac anaesthetic mask, Harvard Apparatus). The ECG was recorded using electrodes attached to the 
two front paws and the back right paw (looking at the belly of the mouse). RR, PR, QT and corrected QT inter-
vals and QRS duration were recorded using a PowerLab/4SP with a ML135 Dual Bio amplifier (ADInstruments).
Echocardiography on anaesthetised mice. Blinded to animal details, transthoracic echocardiography 
was performed on anaesthetised mice using an Acuson Sequoia C256 system (Siemens) and a 14-MHz probe. 
Mice were lightly anaesthetised with ~ 1% isoflurane, maintaining the heart rate at ~ 450 beats/min. M-mode 
parasternal short-axis views were taken to determine left ventricle internal dimension in diastole (LVIDd) and 
systole (LVIDs), posterior wall thickness in diastole (LVPWd) and systole (LVPWs), and interventricular septum 
thickness in diastole (IVSd) and systole (IVSs) over three cardiac cycles; all measurements were in mm. Left 
ventricle fractional shortening (%) was calculated as ((LVIDd − LVIDs)/(LVIDd)) × 100. Left ventricle mass (mg) 
was  calculated90 as 1.05 × ((LVIDd + LVPWd + IVSd)3 − (LVIDd)3).
Tissue electrophysiology. The beating rate of the isolated sinus node was determined by extracellular 
potential recording as described  previously91,92. After sacrifice of a mouse by cervical dislocation, the heart was 
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rapidly removed and placed in Tyrode’s solution containing (in mM): 100 NaCl, 4 KCl, 1.2  MgSO4, 1.2  KH2PO4, 
1.8  CaCl2, 25  NaHCO3 and 10 glucose. The solution was bubbled with 95%  O2 and 5%  CO2 to give a pH of 7.4. 
A right atrial preparation encompassing the sinus node and including the superior vena cava was rapidly dis-
sected and superfused with warm (37 °C) Tyrode’s solution at a rate of 10 ml min−1. Extracellular potentials 
were recorded from the sinus node preparation using two stainless steel pin electrodes (as well as an earth elec-
trode). These recording electrodes interfaced with a Neurolog system (Digitimer) with low-pass and high-pass 
filters adjusted to optimise the signal-to-noise ratio. Extracellular potentials were continuously recorded using 
a PowerLab and LabChart version 7 software (ADInstruments). After dissection, the preparation was allowed 
to stabilise for 30 min and then the mean heart rate was calculated over 500 beats. The effect of 2 mM CsCl on 
the beating rate was studied: the superfusing solution was changed to Tyrode’s solution containing CsCl and, 
after 25 min of treatment, the heart rate was recorded for 5 min. The preparation was then washed with normal 
Tyrode’s solution for 30 min, during which the beating rate approached baseline values.
Sinus node cell isolation and patch clamp. After sacrifice of a mouse, the heart was removed and 
kept in cold Tyrode’s solution during transport. The sinus node was then dissected and cut into 5–6 strips and 
then small square-shaped tissue pieces. The nodal tissues were dissociated into single cells by a standard enzy-
matic and mechanical  procedure93. The tissues were suspended at 35 °C in low  Ca2+/Mg2+ solution containing 
(in mM): 140 NaCl, 5.4 KCl, 0.5  MgCl2, 1.2  KH2PO4, 50 taurine, 5.5 glucose, 5 HEPES–NaOH, pH = 6.9 with 
NaOH. Next the tissues were incubated for 30 min with enzyme solution containing 200 μM  CaCl2, collagenase 
IV (224 U ml−1, Worthington), elastase (1.42 U ml−1, Sigma-Aldrich) and protease (0.45 U ml−1, Sigma-Aldrich) 
dissolved in low  Ca2+/Mg2+ solution. Tissues were washed and incubated for a further 10 min with KB solution 
containing (in mM): 70 L-glutamic acid, 10 DL-beta-hydroxybutyric acid, 10  KH2PO4, 10 taurine, 0.1 EGTA-
KOH, 80 KOH, 20 KCl, 10 HEPES–KOH, pH = 7.4 with KOH. Isolated sinus node cells were stored at 4 °C for 
the day of the experiment in Tyrode’s solution containing (in mM): 140 NaCl, 5.4 KCl, 1.8  CaCl2, 1  MgCl2, 5.5 
glucose, 5 HEPES–NaOH, pH = 7.4 with NaOH. The cells were incubated at 4 °C for 4–6 h with 10 nM miR-
370-3p or scrambled microRNA in Tyrode’s solution. Funny current, If, was recorded from spindle-shaped or 
elongated-spindle shaped cells using a patch electrode in the whole-cell configuration during superfusion of 
Tyrode’s solution.  BaCl2 (1 mM) and  MnCl2 (2 mM) were added to avoid contamination from other ionic cur-
rents. The bath temperature was 35 ± 0.5 °C. The pipette solution contained (in mM): 130 K-aspartate, 10 NaCl, 
2  CaCl2 (pCa = 7), 2  MgCl2, 10 HEPES, 5 EGTA, 2 ATP(Na2), 0.1 GTP, 5 creatine phosphate, pH 7.2. Current was 
recorded during voltage steps to − 35 to − 125 mV from a holding potential of − 35 mV and normalised to cell 
capacitance. Data were acquired at 1 kHz using an Axopatch 200 amplifier and pClamp 8 (Molecular Devices, 
Sunnyvale, CA, USA). Data were analysed off-line using Clampfit 10 (Molecular Devices, Sunnyvale, CA, USA), 
Origin 8 (Origin Lab Corp., Northampton, MA, USA) and GraphPad Prism 6 (GraphPad Software, Inc.).
Sinus node culture. This was carried out as described  previously94. The sinus node was dissected in sterile 
conditions at 37 °C. MicroRNA mimic (mirVana miRNA Mimic; ThermoFisher Scientific) or scrambled micro-
RNA (ThermoFisher Scientific) was mixed with Lipofectamine RNAiMAX Transfection Reagent (ThermoFisher 
Scientific) and injected in the sinus node preparation using a NanoFil 10 μl syringe (World Precision Instru-
ments) at the birfurcation of the sinus node artery. The sinus node preparation was then transferred to sterile 
culture medium and incubated at 37 °C/5%  CO2 for 48 h. Opti-MEM I Reduced Serum Medium (ThermoFisher 
Scientific) was used for the first 10 h and then Advanced DMEM/F-12 (ThermoFisher Scientific) was used for 
the rest of the 48 h. The isolated tissue preparation was thin (< 200 μm) and could be supported by superfusion. 
The culture medium used contained Advanced DMEM/F-12 (Dulbecco’s Modified Eagle Medium/Ham’s F-12, 
Life Technologies), fetal bovine serum (Life Technologies) and l-glutamine-penicillin–streptomycin (Sigma-
Aldrich). Extracellular potentials were recorded from the right atrial appendage using two 0.15 mm diameter 
stainless steel needles (JCM Health) insulated with silicone to within 3–4 mm of the  tips46. The electrodes were 
pinned into opposite sides of the preparation. The culture medium was grounded with a 0.5 mm silver wire 
earth electrode. The electrodes were connected to a Neurolog system (Digitimer) and filtered with suitable low 
and high frequency pass filters. Extracellular potentials were continuously recorded using Powerlab and Chart 
software (ADInstruments). The average rate was calculated via the detection of a deflection greater than two 
standard deviations as a paced beat.
RNA isolation and qPCR.  ~ 1 × 1 mm sinus node tissue samples were taken from isolated preparations 
from the intercaval region opposite the main branch of the crista terminalis. Samples were frozen in liquid  N2 
and stored at − 80 °C until use. Atrial samples (from the right atrial appendage opposite the sinus node) and ven-
tricular samples (from the middle of the left ventricular free wall) were treated in the same way. Total RNA was 
isolated from the samples using the mirVana miRNA Isolation Kit with phenol (Life Technologies) according to 
the manufacturer’s instructions. RNA purity and quantity was determined using a NanoDrop ND-1000 spec-
trophotometer (NanoDrop Technologies). Samples with an OD260/280 reading between 1.8 and 2.1 were used. 
First strand cDNA was synthesised using Superscript II reverse transcriptase (Invitrogen). qPCR was performed 
using an ABI Prism 7,900 HT Sequence Detection System (Applied Biosystems). qPCR for various transcripts 
was carried out using 96-well plates. The reaction mixture comprised 1 μl of cDNA, 1 × Qiagen assay, 1 × SYBR 
Green Master Mix (Applied Biosystems) and DNase-free water. All samples were run in triplicate. The reaction 
conditions were: denaturation step of 95 °C for 10 min followed by 40 cycles of amplification and quantification 
steps of 95 °C for 30 s, 60 °C for 30 s and 72 °C for 1 min. The melt curve conditions were: 95 °C for 15 s, 60 °C for 
15 s and 95 °C for 15 s. mRNA expression normalised to the expression of the reference RNA, 18S, was calculated 
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using the ΔCt method. Stability of three reference RNAs (18S, Ipo8 and HPRT) were evaluated using the algo-
rithm geNorm and 18S was confirmed be the best reference RNA based on its M value (Supplementary Fig. 18).
Reverse transcription, preamplification and qPCR for microRNAs. 138 ng of total RNA from each 
sample was reverse-transcribed using the TaqMan microRNA Reverse Transcription Kit (Cat. No. 4366597) 
and the product (2.5 μl) was preamplified using Megaplex PreAmp Primers Pool A and B (which is a set of pre-
defined pools of 380 stem-looped reverse transcription primers) and TaqMan PreAmp Master Mix (Applied 
Biosystems) in a 25 μl PCR reaction. The preamplification cycling conditions were 95 °C for 10 min, 55 °C for 
2 min and 75 °C for 2 min followed by 12 cycles of 95 °C for 15 s and 60 °C for 4 min. The preamplified cDNA 
was diluted with 0.1 × TE (pH 8.0) to 100 μl and then 10 μl of diluted cDNA was analysed on a TaqMan Array 
Card run on the ABI Prism 7,900 HT Sequence Detection System. qPCR was performed using TaqMan Array 
Rodent MicroRNA A + B Cards Set v3.0 (ThermoFisher Scientific). The two-card set contains a total of 384 
TaqMan microRNA assays per card. The set enables accurate quantitation of 754 rodent miRs. Included on each 
array are three TaqMan microRNA assay endogenous controls to allow data normalisation and one TaqMan 
microRNA assay not related to rodent as a negative control (ath-miR-159a). Results were analysed using RQ 
Manager (Applied Biosystems) and RealTimeStatMiner (Integromics). Average threshold cycle (Ct) values were 
obtained using RQ Manager, and amplification curves were analysed to check for experimental errors. Ct values 
were calculated using automatic baseline settings and a threshold of 0.2. Since a Ct value of 36 represents single 
molecule template detection, Ct values > 36 were considered to be below the detection level of the assay. There-
fore, only the miRNAs with a Ct ≤ 36 were included in the analyses. RealTime StatMiner software was used for 
further analysis: the GeNorm stability score method was used to examine the suitability of the potential refer-
ence miRs for use individually and also in combination; U6 was used. Data were calculated as 2−Ct , where ΔCt 
is ΔCt (reference) − ΔCt (target).
Rather than the TaqMan Array Rodent MicroRNA A + B Cards Set v3.0, in some cases miR-370-3p (short 
form) and miR-139-3p were measured using individual qPCR assays. A combination of U6 and RNU5G was 
used as the reference. The assays used and the target sequences of the assays are shown in Supplementary Table 6.
microRNA bioinformatics. Identification of microRNAs targeting HCN4 was performed using the web-
based software package Ingenuity Pathway Analysis (IPA; Ingenuity Systems). The IPA tool has a microRNA 
target filter function that relies on experimentally validated interactions from the TarBase  database95, miRecords 
(https ://mirec ords.biole ad.org/), TargetScan (https ://www.targe tscan .org/), and manually curated microRNA-
related findings within the IPA knowledgebase. The latter pertains exclusively to information in the published 
scientific literature, whereas the first three methods rely on text mining-assisted curation (TarBase) or algo-
rithms (TargetScan and miRecords) that find mRNA targets by searching for the presence of conserved 8mer 
(≥ 0.8 conserved branch length) and 7mer sites that match the seed region of each  microRNA96. Using this 
approach, we identified miR-128a, miR-139-3p, miR-145-5p, miR-351-3p and miR-370-3p as potentially target-
ing HCN4. Predicted miR-370-3p target binding sites were obtained from RNA22 (https ://cm.jeffe rson.edu/
rna22 /). Potential targets of miR-370-3p were identified using Ingenuity software with TargetScan Mouse v.5.0 
prediction software (https ://www.ingen uity.com/produ cts/ipa).
Isolation and culture of sinus node fibroblasts. A pure culture of sinus node fibroblasts was obtained 
based on a previously described method by Moro et al.97.
Measurement of microRNAs in human sinus node
All human heart tissue research was approved by the Ohio State University Institutional Review Board and was 
in compliance with all relevant ethical regulations. No organs or tissues were procured from prisoners, pregnant 
women or children (< 18 years). Informed consent for tissue collection was obtained from transplant patients and 
families of donors. To prevent any potential identification, human hearts used in this study were de-identified 
and labelled with six-digit random codes for reference. Therefore, investigators are unable to link any specimen 
to any protected health information or individual. Hearts with intact sinus node pacemaker complexes from 
transplant patients (n = 4) and human donor hearts (n = 4) (for patient information see Supplementary Table 3) 
were obtained from the Ohio State University Cardiac Transplant Team or LifeLine of Ohio Organ Procurement 
Organization.
Human sinus node tissue was acquired by a protocol described  previously98. Total RNA was isolated from the 
samples using the mirVana miRNA Isolation Kit with phenol (Life Technologies; catalogue number, AM1560) 
according to the manufacturer’s instructions. RNA purity and quantity was determined using a NanoDrop 
ND-2000 spectrophotometer (NanoDrop Technologies). Samples with an OD260/280 reading between 1.8 and 
2.1 were used. 10 ng of total RNA from each sample was reverse-transcribed using the TaqMan microRNA 
Reverse Transcription Kit (Thermo Fisher Scientific; catalogue number, 4366596) with reverse transcription 
primer from each assay in a 15 μl reverse transcription reaction. The assays were purchased from Thermo Fisher 
Scientific, including TaqMan microRNA Assay has-miR-370 (assay ID, 002275) and TaqMan microRNA Control 
Assay U6 (assay ID, 001973). The reverse transcription cycling conditions were 16 °C for 30 min, 42 °C for 30 min 
and 85 °C for 5 min. Product (1.3 μl) from the reverse transcription reaction was amplified using TaqMan Small 
RNA Assay and TaqMan Universal PCR Master Mix (Thermo Fisher Scientific; catalogue number, 4324018) in 
a 20 μl PCR reaction. qPCR was performed using a BIO-RAD CFX Connect real-time system (Bio-Rad Labo-
ratories) and cycling conditions were 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 
1 min. Average threshold cycle (Ct) values were obtained using CFX Maestro software (Bio-Rad Laboratories) 
and amplification curves were analysed to check for experimental errors. U6 was used as an endogenous control. 
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Data were calculated as  2−ΔCt, where − ΔCt is − (CtmiR-370-3p − CtU6). All samples were run in duplicate, and qPCR 
was repeated three times.
Immunohistochemistry and picrosirius red staining. This was carried out as described  previously99. 
Briefly, sinus node preparations were immersed in optimal cutting temperature compound (VWR) and fro-
zen in liquid  N2. Atrial samples (from right atrial appendage opposite sinus node) and ventricular samples 
(from middle of left ventricular free wall) were treated in the same way. Frozen sections (20 μm) were fixed in 
10% formaldehyde, permeabilised with 0.1% Triton X-100 for 30 min, blocked with 1% bovine serum albumin 
and incubated with anti-HCN4 raised in rabbit (Millipore, AB5808; 1:100). Finally, sections were incubated 
with fluorescein isothiocyanate (FITC) (Millipore, AP182F; 1:100) or CY3 (Millipore, AP182C; 1:400) conju-
gated secondary antibodies raised in rabbit. Immunofluorescent labelling was carried out in batches with each 
batch comprising four slides from sinus node injected with microRNA-370-3p and four slides from sinus node 
injected with scrambled microRNA with three sections per slide. The sections were from approximately the same 
level in the sinus node. Images were collected on a Zeiss Imager Z1 upright confocal microscope. For HCN4 
protein, high magnification images (×63) were collected using the same microscope parameters. 10–15 images 
per region per animal were collected. Picrosirius red staining was carried out on cryosections containing HCN4 
expressing tissue and imaged using a polarizing microscope. Velocity software (Improvision, UK) was used to 
measure the signal intensity (in arbitrary units) for HCN4 and picrosirius red staining. Signal intensity was only 
measured in user-defined regions.
Generation of luciferase reporter gene. To generate the luciferase reporter constructs the mouse HCN4 
exon2 and the partial fragment of mouse HCN4 exon 8, which contained predicted binding sites of miR-370-3p, 
were amplified by PCR and cloned into the pmiR-GLO plasmid (Promega) as 3′-UTR sequence downstream of 
the luciferase gene. Primer sequence for the PCR reactions were as follows:
HCNEx2-FSac 5′ CTC AAT GAG CTC CCT GCC CTC ACT CTC CTG .
HCNEx2-RXho 5′ CGG AGT CTC GAG CAC CTC TTC CCA CTG ATG A.
HCNEx8-FSac 5′ CTC AAT GAG CTC CTC CCC AGG TCC CAC AGC GCA.
HCNEx8-RSal 5′ CGG AGT GTC GAC TGC TCT ACA GAA CAA TAC AAT.
The SacI/XhoI and SacI/SalI restriction sites were incorporated in the primers to facilitate cloning. PCR were 
carried out using mouse genomic DNA (C57Bl/6) as template. We used PfuTurbo Hotstart DNA polymerase 
(Agilent Technologies) following the protocol recommended by the manufacturer. The resulting fragments of 
474 bp (exon 2) and 782 bp (exon 8) were cloned into the pmiRGlo using the restriction sites above. To gener-
ate mutant reporter constructs we conducted site directed mutagenesis using the QuickChange Site Directed 
Mutagenesis Kit (Agilent Technologies) following the manufacturer’s recommendation. Primers used for site 
directed mutagenesis were:
Exon 2 mutant F 5′-GTA CTT CAT CTT GAT CCT CTG CGT TGC AAG GAT GAT TTC TGT GTT GTC C-3′
Exon 2 mutant R 5′-GGA CAA CAC AGA AAT CAT CCT TGC AAC GCA GAG GAT CAA GAT GAA GTA C-3′
Exon 8 mutant F 5′-CGC CAG GTT CCC TCT GGT TGG CAG CAG TAG TCA GAG G-3′
Exon 8 mutant R 5′-CCT CTG ACT ACT GCT GCC AAC CAG AGG GAA CCT GGC G-3′
The predicted exon 2 binding site was mutated from AUC AUC CUUG ACC CGC AGA GGA (wild-type) to 
AUC AUC CUUG CAA CGC AGA GGA (mutant) and the predicted exon 8 binding site was mutated from ACU 
ACU GCUGC ACC CCA GAG GGA (wild-type) to ACU ACU GCUGC CAA CCA GAG GGA—the corresponding 
nucleotides are in bold.
Cell culture, transfection and luciferase reporter assays. We used H9C2 cardiac myoblast cell line 
for the luciferase reporter assay. Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Inv-
itrogen) supplemented with 10% foetal bovine serum and 1% penicillin/streptomycin. 5 × 105 cells/well were 
plated in 24-well plates one day before the transfection. Cells were co-transfected with 0.5 µg of the luciferase 
reporter constructs and 0.5 μg of precursor miR-370-3p or negative control plasmid. Lipofectamine 2000 (Inv-
itrogen) was used for all transfections according to the manufacturer’s instructions. Transfected cells were incu-
bated with DNA:Lipofectamine complexes for 24 h before lysing in passive lysis buffer (Promega) for luciferase 
assay. Luciferase activity was determined using a Luciferase Assay System (Promega) following the manufac-
turer’s recommended protocol and detected using a luminometer (Berthold Technologies Lumat LB 9507). 
Luciferase assays were performed in quadruplicate and repeated three times with an independent batch of cells.
Statistics. For qPCR of mouse cDNA involving microfluidic cards, outliers were automatically filtered using 
RealTime Statminer (v 4.1, Integromics). For qPCR of mouse cDNA involving 96-well plates, the median abso-
lute deviation method was used to identify outliers. In all figures, means ± SEM are shown. Statistical differences 
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were analysed using GraphPad Prism. Differences between two groups were analysed using Student’s unpaired 
t test for parametric data and the Mann–Whitney test for non-parametric data. Differences between more than 
two groups were analysed using one-way or two-way ANOVA followed by a suitable post hoc test in the case of 
parametric data and the Kruskal–Wallis test followed by a suitable post hoc test in the case of non-parametric 
data. Details of tests are given in figure legends.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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